BIONTECH SE SPON. ADRS 1
Commented by Armin Schulz on July 10th, 2025 | 07:15 CEST
How BioNTech, PanGenomic Health, and Pfizer are using artificial intelligence to cut costs and boost returns
Digitalization is revolutionizing the biotechnology and pharmaceutical industries. Artificial intelligence sifts through billions of pieces of medical data in real time, accelerating drug development by years. This is also demonstrated by the new alliance between Moderna and Google Cloud, which are jointly developing an AI platform for customized mRNA cancer therapies. These technologies reduce production costs by up to 40% and generate disruptive return opportunities. At the same time, personalized medicine is opening up billion-dollar markets. Three companies are turning to artificial intelligence to boost their returns: BioNTech, PanGenomic Health, and Pfizer.
Read
Commented by Nico Popp on July 4th, 2025 | 07:10 CEST
Biotech stocks with a safety net and double bottom: Vidac Pharma, BioNTech, and Gilead Sciences
For many years, biotech stocks were considered speculative bets on a single, all-important active ingredient. For seasoned biotech investors, it was once clear that there was little gray area between multiplication and total loss. But the biotech landscape has changed. Innovative technologies and modern processes ensure that even smaller biotech companies have several arrows in their quiver that can hit the mark. We explain what has changed in the biotech sector and what opportunities for collaboration could exist between BioNTech, Gilead Sciences, and Vidac Pharma.
Read
Commented by Mario Hose on July 1st, 2025 | 09:25 CEST
Why Almonty Industries could become the BioNTech of critical metals
Between 2019 and 2021, investors in BioNTech witnessed a prime example of how a strategically relevant product – in this case, the COVID-19 vaccine – became a real stock market rocket thanks to government pressure, political support, and high public expectations. During this period, the share price rose from less than EUR 12.00 to over EUR 397.00. Those who invested early and were patient were able to achieve returns of over 3,200%. The decisive driver was not only technological innovation but also the government's determination to have the population vaccinated multiple times, which secured massive revenues for BioNTech. Today, a strikingly similar scenario is emerging with Almonty Industries (WKN: A1JSSD | ISIN: CA0203981034 | Ticker symbol: ALI) – only this time it is not about vaccines, but about the strategic raw material tungsten, which is indispensable for defense, aerospace, electronics, and mechanical engineering.
Read
Commented by Nico Popp on July 1st, 2025 | 07:00 CEST
Disruption! Everything is changing: BioNxt Solutions, BioNTech, Bio-Rad Laboratories
The outbreak of the COVID-19 pandemic changed many things. True to the motto "just do it," companies like BioNTech have put their faith in mRNA technology—and within months, success followed, along with billions in revenue. Today, there are once again innovations with the potential to turn small companies into major cash cows. We explain what innovative healthcare companies BioNxt Solutions, BioNTech, and Bio-Rad Laboratories are currently working on and what potential this offers investors.
Read
Commented by Fabian Lorenz on June 25th, 2025 | 07:30 CEST
BioNTech swallows CureVac! Evotec and Vidac Pharma next? Price driver takeover and Buy recommendation
Is Vidac Pharma about to see another price explosion? Last fall, the share rose by around 200%. Yesterday, there was a "Buy" recommendation. Analysts see potential for growth in this biotech gem. The latest news on the drug candidate VDA 1102 for brain tumors is promising. Could a takeover be on the cards? CureVac's share price has nearly doubled since the beginning of April. BioNTech plans to acquire its mRNA competitor and thus end patent disputes. Evotec is a permanent fixture on the takeover merry-go-round. However, this currently seems to be the only hope for rising share prices. The management's new strategy has not created the hoped-for wave of optimism. Is it still worth buying now?
Read
Commented by Nico Popp on June 23rd, 2025 | 07:15 CEST
The next cash cow? Quick profits with NetraMark, Moderna, and BioNTech
Do you remember the vaccine race during the coronavirus pandemic? Back then, the duel between BioNTech and CureVac dominated the stock market. Early investors quickly made a fortune. Now, pandemic winner BioNTech aims to swallow up its Swabian competitor. What does this mean, and where is one of the most fascinating industries headed?
Read
Commented by Fabian Lorenz on June 19th, 2025 | 07:05 CEST
Share price speculation thanks to drones and artificial intelligence: Rheinmetall, BioNTech, and NetraMark shares
Drones and artificial intelligence are set to revolutionize entire industries. Listed companies that play a leading role in this transformation hold significant upside potential, such as NetraMark. Using artificial intelligence, the Company helps pharmaceutical and biotech companies shorten development times and reduce costs. NetraMark also aims to help shape industry trends. BioNTech, too, relies on AI for its research, frequently acquiring specialized companies. Perhaps NetraMark will be next? In any case, the Canadians would still be a bargain. Rheinmetall shares, on the other hand, are certainly not cheap. However, the multibillion-euro defense budgets for rearmament in Europe are fueling speculation. In order to be able to deliver not only tanks, howitzers, and ammunition quickly, but also cutting-edge technology, Germany's largest defense contractor is focusing on partnerships. This is evident in its latest partnership, which is expected to enable Rheinmetall to deliver combat and kamikaze drones quickly.
Read
Commented by André Will-Laudien on June 17th, 2025 | 07:05 CEST
Takeovers! A new dawn for biotech companies – Evotec, BioNTech, PanGenomic Health, and CureVac in focus
Many large pharmaceutical companies are facing the "patent cliff" as patents on blockbuster drugs expire, threatening massive revenue losses in the future. To fill these gaps, they are acquiring suitable and innovative biotech companies with promising drug pipelines. Sometimes, however, they simply acquire technologies already worth billions. The current wave of acquisitions in the biotech sector is being driven by a combination of economic pressure, technological change toward AI and digitalization, and a weak financing environment for smaller biotech companies. After years of restraint and high volatility, fundamental valuation factors are back in focus. Investors are returning, creating a prosperous environment for those who jump on the bandwagon in time. We highlight a few ideas.
Read
Commented by Armin Schulz on June 16th, 2025 | 07:10 CEST
Benefit from the biotech boom: Why Evotec, BioNxt Solutions & BioNTech could be the next winners
The biotech sector is pulsating with unique dynamism while traditional markets are faltering. The drivers are billion-dollar acquisitions, groundbreaking research, and strategic alliances. Large pharmaceutical companies are eagerly securing access to innovations. Analysts agree: strong patent portfolios and innovative partnerships are crucial for future growth. These protect valuable therapeutic developments and enable even smaller players to scale globally. For investors, this robust, capital-rich industry offers enormous opportunities. Those who identify the right innovators early on can reap above-average profits. Three companies embody this momentum: Evotec, BioNxt Solutions, and BioNTech.
Read
Commented by Fabian Lorenz on June 9th, 2025 | 07:15 CEST
BioNTech billion-dollar deal a template for BioNxt Solutions? Bayer shares recommended as a buy!
The billion-dollar deal between BioNTech and Bristol-Myers Squibb was a real bombshell and has revitalized the biotech industry. While analysts are raising their price targets for the German biotech high-flyer, there are also critical voices. Investors are also wondering where Big Pharma will strike next. One potential candidate for a partnership is BioNxt Solutions. The Company aims to simplify drug administration using oral dissolvable films, skin patches, and tablets. Clinical trials are about to begin on the development of its lead product for the easier treatment of multiple sclerosis, and a key patent has just been granted in Europe. Due to its low valuation and universal application possibilities, a complete takeover is also conceivable. And what is Bayer doing? Despite numerous legal proceedings, the stock is performing well in 2025. Analysts see further upside potential and have upgraded the stock.
Read